These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 1694236

  • 1. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
    Champlin R, Gajewski J, Nimer S, Vollset S, Landaw E, Winston D, Schiller G, Ho W.
    J Clin Oncol; 1990 Jul; 8(7):1199-206. PubMed ID: 1694236
    [Abstract] [Full Text] [Related]

  • 2. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
    Amadori S, Testi AM, Aricò M, Comelli A, Giuliano M, Madon E, Masera G, Rondelli R, Zanesco L, Mandelli F.
    J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
    [Abstract] [Full Text] [Related]

  • 3. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
    Jehn U.
    Leuk Lymphoma; 1994 Sep; 15(1-2):99-112. PubMed ID: 7532060
    [Abstract] [Full Text] [Related]

  • 4. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 5. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug 15; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 6. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.
    Phillips GL, Reece DE, Shepherd JD, Barnett MJ, Brown RA, Frei-Lahr DA, Klingemann HG, Bolwell BJ, Spinelli JJ, Herzig RH.
    Blood; 1991 Apr 01; 77(7):1429-35. PubMed ID: 2009367
    [Abstract] [Full Text] [Related]

  • 7. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
    Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G.
    N Engl J Med; 1995 Jan 26; 332(4):217-23. PubMed ID: 7808487
    [Abstract] [Full Text] [Related]

  • 8. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission.
    Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL.
    J Clin Oncol; 1992 Jan 26; 10(1):41-6. PubMed ID: 1727924
    [Abstract] [Full Text] [Related]

  • 9. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
    Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A.
    Blood; 1999 Jun 15; 93(12):4116-24. PubMed ID: 10361108
    [Abstract] [Full Text] [Related]

  • 10. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G, Link H, Schönrock-Nabulsi P, Wandt H, Gramatzki M, Löffler B, Fackler-Schwalbe I, Queisser W, Brack N, Geer T, Raab M, Ohl S, Schneider B, Schneider C, Freund M, Poliwoda H, Ehninger G.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():26-32. PubMed ID: 8692115
    [Abstract] [Full Text] [Related]

  • 11. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R.
    J Clin Oncol; 1998 Mar 12; 16(3):872-81. PubMed ID: 9508168
    [Abstract] [Full Text] [Related]

  • 12. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
    Bow EJ, Kilpatrick MG, Scott BA, Clinch JJ, Cheang MS.
    Cancer; 1994 Jul 01; 74(1):52-60. PubMed ID: 8004583
    [Abstract] [Full Text] [Related]

  • 13. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
    Champlin R, Jacobs A, Gale RP, Boccia R, Elashoff R, Foon K, Zighelboim J.
    Lancet; 1984 Apr 21; 1(8382):894-6. PubMed ID: 6200742
    [Abstract] [Full Text] [Related]

  • 14. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 15. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
    Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, Einsele H, Ho AD, Serve H, Berdel WE, Mayer J, Schmitz N, Krause SW, Neubauer A, Baldus CD, Schetelig J, Bornhäuser M, Ehninger G.
    J Clin Oncol; 2013 Jun 10; 31(17):2094-102. PubMed ID: 23630210
    [Abstract] [Full Text] [Related]

  • 16. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results.
    Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP.
    J Clin Oncol; 1989 Sep 10; 7(9):1260-7. PubMed ID: 2769327
    [Abstract] [Full Text] [Related]

  • 17. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E, Arlin ZA, Gaynor J, Miller W, Gee T, Kempin SJ, Mertelsmann R, Andreeff M, Reich L, Nahmias N.
    Leukemia; 1989 Feb 10; 3(2):115-21. PubMed ID: 2911205
    [Abstract] [Full Text] [Related]

  • 18. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
    Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA.
    J Clin Oncol; 2013 Mar 01; 31(7):923-9. PubMed ID: 23129738
    [Abstract] [Full Text] [Related]

  • 19. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
    Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D.
    J Clin Oncol; 2013 Sep 20; 31(27):3360-8. PubMed ID: 23940227
    [Abstract] [Full Text] [Related]

  • 20. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T.
    J Clin Oncol; 2014 Jan 20; 32(3):219-28. PubMed ID: 24297940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.